Computed tomography-guided frameless stereotactic radiotherapy for Stage Inon-small-cell lung cancer: A 5-year experience

Citation
M. Uematsu et al., Computed tomography-guided frameless stereotactic radiotherapy for Stage Inon-small-cell lung cancer: A 5-year experience, INT J RAD O, 51(3), 2001, pp. 666-670
Citations number
13
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
0360-3016 → ACNP
Volume
51
Issue
3
Year of publication
2001
Pages
666 - 670
Database
ISI
SICI code
0360-3016(20011101)51:3<666:CTFSRF>2.0.ZU;2-Y
Abstract
Purpose: Stereotactic radiotherapy (SRT) is highly effective for brain meta stases from non-small-cell lung cancers (NSCLCs). As such, primary lesions of NSCLC may also be treated effectively by similar focal high-dose SRT. Methods and Materials: Between October 1994 and June 1999, 50 patients with pathologically proven T1-2N0 MO NSCLC were treated by CT-guided frameless SRT. Of these, 21 patients were medically inoperable and the remainder were medically operable but refused surgery. In most patients, SRT was 50-60 Gy in 5-10 fractions for 1-2 weeks. Eighteen patients also received conventio nal radiotherapy of 40-60 Gy in 20-33 fractions before SRT. Results: With a median follow-up period of 36 months (range 22-66), 30 pati ents were alive and disease free, 3 were alive with disease, 6 had died of disease, and 11 had died intercurrently. Local progression was not observed on follow-up CT scans in 47 (94%) of 50 patients. The 3-year overall survi val rate was 66% in all 50 patients and 86% in the 29 medically operable pa tients. The 3-year cause-specific survival rate of all 50 patients was 88%. No definite adverse effects related to SRT were noted, except for 2 patien ts with a minor bone fracture and 6 patients with temporary pleural pain. Conclusions: SRT is a very safe and effective treatment for Stage I NSCLC. Additional studies involving a larger patient population and longer follow- up periods are warranted to assess this new treatment for early-stage lung cancer. (C) 2001 Elsevier Science Inc.